

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peter KUFER, et al.
Title: LESS IMMUNOGENIC BINDING MOLECULES
Application No.: 10/588,734
Filing Date: February 16, 2005
Examiner: Unassigned
Art Unit: Unassigned
Confirmation No.: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 C.F.R. §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 C.F.R. §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

Documents B1-B30 were cited in the specification of the present application. Documents B1-B14, B16-B19, and B21-B30 are in English. Document B15 is in German and document B20 is in Japanese. Relevance for documents B15 and B20 can be found in the specification of the present application.

No English translation is available for documents B15 or B20; however English abstracts are provided. The absence of a translation does not relieve the PTO from its duty to consider the submitted document (37 CFR §1.98 and M.P.E.P. § 609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicants believe that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date March 30, 2007

By Richard C. Peet

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5483
Facsimile: (202) 672-5399

Richard C. Peet
Attorney for Applicant
Registration No. 35,792

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>April 6, 2007</u> (use as many sheets as necessary)				Complete if Known	
				Application Number	10/588,734
				Filing Date	2/16/2005
				First Named Inventor	Peter KUFER
				Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	028622-0155
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	B1	5,565,322 A	10-15-1996	Heller	
	B2	5,585,097 A	12-17-1996	Bolt et al.	
	B3	5,834,597 A	11-10-1998	Tso et al.	
	B4	5,859,205 A	01-12-1999	Adair et al.	
	B5	5,885,573 A	03-23-1999	Bluestone et al.	
	B6	5,929,212 A	07-27-1999	Jolliffe et al.	
	B7	6,407,213 B1	06-18-2002	Carter et al.	
	B8	2002/0131968 A1	09-19-2002	Waldmann et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	B9	EP 0 460 167 B1	10-11-1995	Celltech Therapeutics Limited		
	B10	EP 0 519 596 B1	02-23-2005	Merck & Co., Inc. National Institutes of Health		
	B11	EP 0 592 106 A1	04-13-1994	Immunogen, Inc.		
	B12	EP 0 626 390 B1	11-14-2001	Celltech Therapeutics Limited		
	B13	EP 0 940 468 A1	09-08-1999	Genentech, Inc.		
	B14	EP 0 971 959 B1	12-28-2005	Genentech, Inc.		
	B15	EP 1,025,854	08-09-2000	GSF-Forschungszentrum fur Umwelt und Gesundheit GmbH		
	B16	WO 91/09967 A1	07-11-1991	Celltech Limited		
	B17	WO 91/09968 A1	07-11-1991	Celltech Limited		
	B18	WO 92/22653 A1	12-23-1992	Genentech, Inc.		
	B19	WO 00/05268 A1	02-03-2000	BTG International Ltd.		
	B20	WO 03/04648 A1	01-16-2003	Institute of Genetics and Devel. Biol. (Beijing ABT Genetic Engineering Technology Co., Ltd.)		

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <u>April 6, 2007</u> (use as many sheets as necessary)		Application Number	10/588,734
		Filing Date	2/16/2005
		First Named Inventor	Peter KUFER
		Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	028622-0155
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	B21	ADAIR et al., "Humanization of the Murine Anti-Human CD3 Monoclonal Antibody OKT3," <i>Hum. Antibod. Hybridomas</i> , vol. 5, 1 and 2, 1994, pp. 41-47.	
	B22	BRÜHL et al., "Depletion of CCR5-Expressing Cells with Bispecific Antibodies and Chemokine Toxins: a New Strategy in the Treatment of Chronic Inflammatory Diseases and HIV," <i>Journal of Immunology</i> , vol. 166, no. 4, Feb. 15, 2001, pp. 2420-2426.	
	B23	HOFFMAN et al., "Lysis of Anti-T3-Bearing Murine Hybridoma Cells by Human Allospecific Cytotoxic T Cell Clones and Inhibition of that Lysis by Anti-T3 and Anti-LFA-1 Antibodies," <i>The Journal of Immunology</i> , vol. 135, no. 1, Jul. 1985, pp. 5-8.	
	B24	KIPRIYANOV, et al., "Bispecific CD3 X CD19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells," <i>Int. J. Cancer</i> , vol. 77, 1998, pp. 763-772.	
	B25	KUFER et al., "Construction and Biological Activity of a Recombinant Bispecific Single-Chain Antibody Designed for Therapy of Minimal Residual Colorectal Cancer," <i>Cancer Immunol Immunother</i> , vol. 45, 1997, pp. 193-197.	
	B26	LÖFFLER, et al. "A Recombinant Bispecific Single-Chain Antibody, CD19 X CD3, Induces Rapid and High Lymphoma-Directed Cytotoxicity by Unstimulated T Lymphocytes," <i>Blood</i> , vol. 95, no. 6, Mar. 15, 2000, pp. 2098-2103.	
	B27	MACK et al., "Biologic Properties of a Bispecific Single-Chain Antibody Directed Against 17-1A (EpCAM) and CD3," <i>The Journal of Immunology</i> , vol. 58, 1997, pp. 3965-3970.	
	B28	RAUM et al., "Anti-Self Antibodies Selected from a Human IgD Heavy Chain Repertoire: a Novel Approach to Generate Therapeutic Human Antibodies Against Tumor-Associated Differentiation Antigens," <i>Cancer Immunol Immunother</i> , vol. 50, 2001, pp. 141-150.	
	B29	RIECHMANN et al., "Reshaping Human Antibodies for Therapy," <i>Nature</i> , vol. 332, Mar. 24, 1988, pp. 323-327.	
	B30	TRAUNECKER et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells," <i>The EMBO Journal</i> , vol. 10, no. 12, 1991, pp. 3655-3659.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.